Sagimet Biosciences Inc. (SGMT) Stock Price & Analysis
Sagimet Biosciences Inc. (SGMT) fell 2.10% to USD 10.71 as of September 9, 2026 at 13:27 UTC, according to Nexqual real-time market data.
SGMT last closed at USD 10.94; the session ranged USD 10.65–11.17 on volume of 804,361 shares. Market capitalization is $665.72M, with a 52-week range of USD 4.5–11.24 (NGM). Source: Nexqual, September 9, 2026 at 13:27 UTC.
Key Statistics (as of September 9, 2026 at 13:27 UTC)
| Price | USD 10.71 |
|---|---|
| Change | ▼ 2.10% (down) |
| Previous Close | USD 10.94 |
| Open | USD 10.76 |
| Day Range | USD 10.65 – 11.17 |
| 52-Week Range | USD 4.5 – 11.24 |
| Volume | 804,361 shares |
| Market Cap | $665.72M |
| Exchange | NGM |
Technical Analysis (SGMT)
Nexqual's technical model rates SGMT "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 13:27 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 65.72 (neutral) |
| vs SMA50 | Above (USD 8.74) |
| MACD | 0.63 (positive) |
Analyst Ratings (SGMT)
Wall Street analysts rate SGMT "Strong Buy" based on 10 analysts, with a mean price target of USD 28.6 (range USD 8–56), per Nexqual as of September 9, 2026 at 13:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 28.6 |
| High Target | USD 56 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (SGMT)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.26 vs est -0.27 ▲ beat |
| 2026-03-31 | USD -0.33 vs est -0.35 ▲ beat |
| 2025-12-31 | USD -0.29 vs est -0.4 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.39 ▼ miss |
Source: Nexqual, September 9, 2026 at 13:27 UTC.
Financials & Fundamentals (SGMT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -24.37% |
| Debt / Equity | 0.76 |
| Current Ratio | 45.03 |
| Total Cash | $240.13M |
| Total Debt | $1.94M |
| Free Cash Flow | $-27.82M |
Source: Nexqual, September 9, 2026 at 13:27 UTC.
Financial Health Score (SGMT)
Nexqual rates Sagimet Biosciences Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 13:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $240M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$42M |
| Efficiency | Critical — ROE -24%, ROA -16.4% |
Ownership (SGMT)
| Insider Ownership | +3.35% |
|---|---|
| Institutional Ownership | +83.10% |
| Shares Outstanding | 61.59M |
| Float | 55.78M |
| Short % of Float | +19.23% |
Source: Nexqual, September 9, 2026 at 13:27 UTC.
Leadership (SGMT)
Sagimet Biosciences Inc. is led by David A. Happel (age 63), CEO, President & Director, per Nexqual as of September 9, 2026 at 13:27 UTC.
| CEO, President & Director | David A. Happel (age 63) |
|---|---|
| CFO & Principal Accounting Officer | Thierry Chauche (age 49) |
| Chief Scientific Officer | Marie O'Farrell |
| Senior Vice President of New Products | Robert D'Urso |
Major Backers & Investors (SGMT)
Notable institutional backers of Sagimet Biosciences Inc. include Federated Hermes, Inc., Balyasny Asset Management LP, Woodline Partners LP, according to Nexqual as of September 9, 2026 at 13:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Federated Hermes, Inc. | 6.77% |
| Balyasny Asset Management LP | 5.89% |
| Woodline Partners LP | 4.87% |
| SilverArc Capital Management, LLC | 4.75% |
| Affinity Asset Advisors, Llc | 4.06% |
| BVF Inc. | 4.06% |
| Caligan Partners, LP | 4.06% |
| Great Point Partners LLC | 3.3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.43% |
| Vanguard Group | 8.26% |
Source: Nexqual, September 9, 2026 at 13:27 UTC.
From Sagimet Biosciences Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- These trials would allow us to evaluate potential improvements in non-invasive biomarkers directly in MASH patients and select combinations for further development.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TVGN | Tevogen Inc. | USD 7.33 | ▲ 2.23% |
| BDRX | Biodexa Pharmaceuticals plc | USD 0.83 | ▲ 4.14% |
| LRHC | La Rosa Holdings Corp. | USD 3.02 | ▲ 549.46% |
| INBS | Intelligent Bio Solutions Inc. | USD 2.15 | ▼ 6.52% |
| CMND | Clearmind Medicine Inc. | USD 1.03 | ▼ 39.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 13:27 UTC. This page is informational and not investment advice.